|
Display Options:
|
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Retinoid isomerohydrolase inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Geographic Atrophy; Macular Degeneration; Stargardt Disease
EMIXUSTAT
×| Maximum Phase: 3 |
| First Approval: None |
| UNII: 02DZ1HBF0M |
| Molecule Type: Small molecule |
| Molecular Formula: C16H25NO2 |
| Molecular Weight: 263.38 |
| AlogP: 3.03 |
| PSA: 55.48 |
| HBD: 2.0 |
| HBA: |
| #RotB: 6.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Neoplasms; Carcinoma, Squamous Cell; Esophageal Neoplasms; Myelodysplastic Syndromes; Anemia, Refractory, with Excess of Blasts
RIGOSERTIB
×| Maximum Phase: 3 |
| First Approval: None |
| UNII: 67DOW7F9GL |
| Molecule Type: Small molecule |
| Molecular Formula: C21H25NO8S |
| Molecular Weight: 451.5 |
| AlogP: 2.8 |
| PSA: 120.39 |
| HBD: 2.0 |
| HBA: |
| #RotB: 11.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
SESAME OIL
×| Maximum Phase: 3 |
| First Approval: None |
| UNII: QX10HYY4QV |
| Molecule Type: Small molecule |
| Molecular Formula: |
| Molecular Weight: |
| AlogP: |
| PSA: |
| HBD: |
| HBA: |
| #RotB: |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Nischarin agonist
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Hypertension
RILMENIDINE
×| Maximum Phase: 3 |
| First Approval: None |
| UNII: P67IM25ID8 |
| Molecule Type: Small molecule |
| Molecular Formula: C10H16N2O |
| Molecular Weight: 180.25 |
| AlogP: 1.15 |
| PSA: 33.62 |
| HBD: 1.0 |
| HBA: |
| #RotB: 3.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Thromboxane A2 receptor antagonist
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
TERUTROBAN
×| Maximum Phase: 3 |
| First Approval: None |
| UNII: A6WX9391D8 |
| Molecule Type: Small molecule |
| Molecular Formula: C20H22ClNO4S |
| Molecular Weight: 407.92 |
| AlogP: 3.5 |
| PSA: 83.47 |
| HBD: 2.0 |
| HBA: |
| #RotB: 6.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Lung Neoplasms; Neural Tube Defects; Alzheimer Disease; Carcinoma, Non-Small-Cell Lung; Hemorrhage; Metabolic Syndrome; Trichotillomania; Diabetes Mellitus, Type 1; Retinopathy of Prematurity
INOSITOL
×| Maximum Phase: 3 |
| First Approval: None |
| UNII: 4L6452S749 |
| Molecule Type: Small molecule |
| Molecular Formula: C6H12O6 |
| Molecular Weight: 180.16 |
| AlogP: -3.83 |
| PSA: 121.38 |
| HBD: 6.0 |
| HBA: |
| #RotB: 0.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
TETRAFILCON A
×| Maximum Phase: 3 |
| First Approval: None |
| UNII: None |
| Molecule Type: Small molecule |
| Molecular Formula: |
| Molecular Weight: |
| AlogP: |
| PSA: |
| HBD: |
| HBA: |
| #RotB: |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Glucocorticoid receptor agonist
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Eye Diseases; Psoriasis; Conjunctivitis, Allergic; Dermatitis, Atopic; Dry Eye Syndromes; Cataract
MAPRACORAT
×| Maximum Phase: 3 |
| First Approval: None |
| UNII: 145V79YBVP |
| Molecule Type: Small molecule |
| Molecular Formula: C25H26F4N2O2 |
| Molecular Weight: 462.49 |
| AlogP: 5.69 |
| PSA: 54.38 |
| HBD: 2.0 |
| HBA: |
| #RotB: 6.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Anxiety; Dementia; Depressive Disorder; Schizophrenia
OPIPRAMOL
×| Maximum Phase: 3 |
| First Approval: None |
| UNII: D23ZXO613C |
| Molecule Type: Small molecule |
| Molecular Formula: C23H29N3O |
| Molecular Weight: 363.5 |
| AlogP: 3.31 |
| PSA: 29.95 |
| HBD: 1.0 |
| HBA: |
| #RotB: 6.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Conjunctivitis, Allergic; Dry Eye Syndromes; Sjogren-Larsson Syndrome
REPROXALAP
×| Maximum Phase: 3 |
| First Approval: None |
| UNII: F0GIZ22IJH |
| Molecule Type: Small molecule |
| Molecular Formula: C12H13ClN2O |
| Molecular Weight: 236.7 |
| AlogP: 2.7 |
| PSA: 59.14 |
| HBD: 2.0 |
| HBA: |
| #RotB: 1.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung
P-TOLUENESULFONAMIDE
×| Maximum Phase: 3 |
| First Approval: None |
| UNII: I8266RI90M |
| Molecule Type: Small molecule |
| Molecular Formula: C7H9NO2S |
| Molecular Weight: 171.22 |
| AlogP: 0.64 |
| PSA: 60.16 |
| HBD: 1.0 |
| HBA: |
| #RotB: 1.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Tachycardia, Ventricular; Ventricular Fibrillation
CELIVARONE
×| Maximum Phase: 3 |
| First Approval: None |
| UNII: K45001587E |
| Molecule Type: Small molecule |
| Molecular Formula: C34H47NO4 |
| Molecular Weight: 533.75 |
| AlogP: 8.41 |
| PSA: 59.75 |
| HBD: 0.0 |
| HBA: |
| #RotB: 17.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Sodium/glucose cotransporter 2 inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Liver Diseases; Atrial Fibrillation; Diabetes Mellitus, Type 2
HENAGLIFLOZIN
×| Maximum Phase: 3 |
| First Approval: None |
| UNII: 21P2M98388 |
| Molecule Type: Small molecule |
| Molecular Formula: C22H24ClFO7 |
| Molecular Weight: 454.88 |
| AlogP: 1.5 |
| PSA: 108.61 |
| HBD: 4.0 |
| HBA: |
| #RotB: 6.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Neoplasms; Breast Neoplasms; Multiple Myeloma; Pancreatic Neoplasms; Fibromatosis, Aggressive
NIROGACESTAT
×| Maximum Phase: 3 |
| First Approval: None |
| UNII: QZ62892OFJ |
| Molecule Type: Small molecule |
| Molecular Formula: C27H41F2N5O |
| Molecular Weight: 489.66 |
| AlogP: 4.79 |
| PSA: 70.98 |
| HBD: 3.0 |
| HBA: |
| #RotB: 10.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Adenocarcinoma of Lung; Head and Neck Neoplasms; Prostatic Neoplasms, Castration-Resistant; Renal Insufficiency, Chronic; Breast Neoplasms; Menopause
ISOFLAVONE
×| Maximum Phase: 3 |
| First Approval: None |
| UNII: OVO2KUW8H8 |
| Molecule Type: Small molecule |
| Molecular Formula: C15H10O2 |
| Molecular Weight: 222.24 |
| AlogP: 3.46 |
| PSA: 30.21 |
| HBD: 0.0 |
| HBA: |
| #RotB: 1.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Solute carrier family 22 member 12 inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Renal Insufficiency; Hyperuricemia; Gout
DOTINURAD
×| Maximum Phase: 3 |
| First Approval: None |
| UNII: 305EB53128 |
| Molecule Type: Small molecule |
| Molecular Formula: C14H9Cl2NO4S |
| Molecular Weight: 358.2 |
| AlogP: 3.09 |
| PSA: 74.68 |
| HBD: 1.0 |
| HBA: |
| #RotB: 1.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Fibroblast growth factor receptor inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Breast Neoplasms; Colorectal Neoplasms; Kidney Neoplasms; Lung Neoplasms; Multiple Myeloma; Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Stomach Neoplasms; Carcinoma, Hepatocellular
ORANTINIB
×| Maximum Phase: 3 |
| First Approval: None |
| UNII: 9RL37ZZ665 |
| Molecule Type: Small molecule |
| Molecular Formula: C18H18N2O3 |
| Molecular Weight: 310.35 |
| AlogP: 3.14 |
| PSA: 82.19 |
| HBD: 3.0 |
| HBA: |
| #RotB: 4.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Epidermal growth factor receptor erbB1 inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Adenocarcinoma of Lung; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung
ALFLUTINIB
×| Maximum Phase: 3 |
| First Approval: None |
| UNII: A49A7A5YN4 |
| Molecule Type: Small molecule |
| Molecular Formula: C28H31F3N8O2 |
| Molecular Weight: 568.6 |
| AlogP: 4.84 |
| PSA: 100.44 |
| HBD: 2.0 |
| HBA: |
| #RotB: 11.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
TRANSPLATIN
×| Maximum Phase: 3 |
| First Approval: None |
| UNII: BW0OY6ZTD4 |
| Molecule Type: Small molecule |
| Molecular Formula: H6Cl2N2Pt |
| Molecular Weight: 300.05 |
| AlogP: None |
| PSA: None |
| HBD: None |
| HBA: |
| #RotB: None |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
OCUFILCON D
×| Maximum Phase: 3 |
| First Approval: None |
| UNII: None |
| Molecule Type: Small molecule |
| Molecular Formula: |
| Molecular Weight: |
| AlogP: |
| PSA: |
| HBD: |
| HBA: |
| #RotB: |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Peroxisome proliferator-activated receptor alpha agonist
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Kidney Diseases; Liver Cirrhosis; Liver Diseases; Lipid Metabolism Disorders; Liver Cirrhosis, Biliary; Non-alcoholic Fatty Liver Disease; Fatty Liver
SAROGLITAZAR
×| Maximum Phase: 3 |
| First Approval: None |
| UNII: E0YMX3S4JD |
| Molecule Type: Small molecule |
| Molecular Formula: C25H29NO4S |
| Molecular Weight: 439.58 |
| AlogP: 5.3 |
| PSA: 60.69 |
| HBD: 1.0 |
| HBA: |
| #RotB: 11.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Tinnitus; Alzheimer Disease
NERAMEXANE
×| Maximum Phase: 3 |
| First Approval: None |
| UNII: 856DX0KJ84 |
| Molecule Type: Small molecule |
| Molecular Formula: C11H23N |
| Molecular Weight: 169.31 |
| AlogP: 2.94 |
| PSA: 26.02 |
| HBD: 1.0 |
| HBA: |
| #RotB: 0.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
GALYFILCON A
×| Maximum Phase: 3 |
| First Approval: None |
| UNII: None |
| Molecule Type: Small molecule |
| Molecular Formula: |
| Molecular Weight: |
| AlogP: |
| PSA: |
| HBD: |
| HBA: |
| #RotB: |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Dry Eye Syndromes
FONADELPAR
×| Maximum Phase: 3 |
| First Approval: None |
| UNII: FK5ZAD810Z |
| Molecule Type: Small molecule |
| Molecular Formula: C25H23F3N2O4S |
| Molecular Weight: 504.53 |
| AlogP: 6.65 |
| PSA: 85.45 |
| HBD: 1.0 |
| HBA: |
| #RotB: 8.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Neuronal acetylcholine receptor; alpha4/beta2 partial agonist
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Smoking Cessation; Tobacco Use Disorder
CYTISINICLINE
×| Maximum Phase: 3 |
| First Approval: None |
| UNII: 53S5U404NU |
| Molecule Type: Small molecule |
| Molecular Formula: C11H14N2O |
| Molecular Weight: 190.25 |
| AlogP: 0.55 |
| PSA: 34.03 |
| HBD: 1.0 |
| HBA: |
| #RotB: 0.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Surfactant
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
ASTODRIMER
×| Maximum Phase: 3 |
| First Approval: None |
| UNII: F8H3J9KSY9 |
| Molecule Type: Small molecule |
| Molecular Formula: |
| Molecular Weight: |
| AlogP: |
| PSA: |
| HBD: |
| HBA: |
| #RotB: |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
CLAMOXYQUIN
×| Maximum Phase: 3 |
| First Approval: None |
| UNII: JUN13FZ6RF |
| Molecule Type: Small molecule |
| Molecular Formula: C17H24ClN3O |
| Molecular Weight: 321.85 |
| AlogP: 3.42 |
| PSA: 48.39 |
| HBD: 2.0 |
| HBA: |
| #RotB: 8.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Monoamine transporter inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Depressive Disorder, Major; Attention Deficit Disorder with Hyperactivity; Feeding and Eating Disorders
DASOTRALINE
×| Maximum Phase: 3 |
| First Approval: None |
| UNII: 4D28EY0L5T |
| Molecule Type: Small molecule |
| Molecular Formula: C16H15Cl2N |
| Molecular Weight: 292.21 |
| AlogP: 4.92 |
| PSA: 26.02 |
| HBD: 1.0 |
| HBA: |
| #RotB: 1.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Multiple Myeloma; Sarcoma, Ewing
(R)-MELPHALAN
×| Maximum Phase: 3 |
| First Approval: None |
| UNII: 94H892992X |
| Molecule Type: Small molecule |
| Molecular Formula: C13H18Cl2N2O2 |
| Molecular Weight: 305.21 |
| AlogP: 1.93 |
| PSA: 66.56 |
| HBD: 2.0 |
| HBA: |
| #RotB: 8.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Endothelin receptor ET-A antagonist
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Hypertension
DARUSENTAN
×| Maximum Phase: 3 |
| First Approval: None |
| UNII: 33JD57L6RW |
| Molecule Type: Small molecule |
| Molecular Formula: C22H22N2O6 |
| Molecular Weight: 410.43 |
| AlogP: 2.92 |
| PSA: 100.0 |
| HBD: 1.0 |
| HBA: |
| #RotB: 9.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: FK506-binding protein 1A inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
ZOTAROLIMUS
×| Maximum Phase: 3 |
| First Approval: None |
| UNII: H4GXR80IZE |
| Molecule Type: Small molecule |
| Molecular Formula: C52H79N5O12 |
| Molecular Weight: 966.23 |
| AlogP: 6.05 |
| PSA: 218.8 |
| HBD: 2.0 |
| HBA: |
| #RotB: 7.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Heart Failure, Systolic; Hypertension; Inflammation; Acute Kidney Injury; Aging; Erythromelalgia; Heart Failure; Peripheral Nervous System Diseases; Premature Birth; Peripheral Arterial Disease
NICOTINAMIDE RIBOSIDE
×| Maximum Phase: 3 |
| First Approval: None |
| UNII: 0I8H2M0L7N |
| Molecule Type: Small molecule |
| Molecular Formula: C11H15N2O5+ |
| Molecular Weight: 255.25 |
| AlogP: -2.32 |
| PSA: 116.89 |
| HBD: 4.0 |
| HBA: |
| #RotB: 3.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Progesterone receptor modulator
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Endometriosis; Leiomyoma
VILAPRISAN
×| Maximum Phase: 3 |
| First Approval: None |
| UNII: IN59K53GI9 |
| Molecule Type: Small molecule |
| Molecular Formula: C27H29F5O4S |
| Molecular Weight: 544.58 |
| AlogP: 5.92 |
| PSA: 71.44 |
| HBD: 1.0 |
| HBA: |
| #RotB: 3.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Nuclear factor NF-kappa-B complex inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Diabetes Mellitus, Type 2; Muscular Dystrophy, Duchenne
EDASALONEXENT
×| Maximum Phase: 3 |
| First Approval: None |
| UNII: AF3Z6434KS |
| Molecule Type: Small molecule |
| Molecular Formula: C31H42N2O3 |
| Molecular Weight: 490.69 |
| AlogP: 6.72 |
| PSA: 78.43 |
| HBD: 3.0 |
| HBA: |
| #RotB: 18.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Shock, Septic
ADENINE
×| Maximum Phase: 3 |
| First Approval: None |
| UNII: JAC85A2161 |
| Molecule Type: Small molecule |
| Molecular Formula: C5H5N5 |
| Molecular Weight: 135.13 |
| AlogP: -0.06 |
| PSA: 80.48 |
| HBD: 2.0 |
| HBA: |
| #RotB: 0.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Prostatic Neoplasms, Castration-Resistant; Breast Neoplasms; Leukemia, Myeloid, Acute
AMONAFIDE
×| Maximum Phase: 3 |
| First Approval: None |
| UNII: 1Q8D39N37L |
| Molecule Type: Small molecule |
| Molecular Formula: C16H17N3O2 |
| Molecular Weight: 283.33 |
| AlogP: 1.58 |
| PSA: 66.64 |
| HBD: 1.0 |
| HBA: |
| #RotB: 3.0 |
| Source: |